A Randomized Phase II Study of Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy According to EGFR Mutation Status in Patients With Unresectable Stage III NSCLC.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Irinotecan
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Oct 2010 Planned end date changed from Mar 2011 to Mar 2015 as reported by ClinicalTrials.gov.
- 26 Mar 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History